Blog

The latest thoughts from Medicines Law & Policy partners.

Updated TRIPS Flexibilities Database

In January 2023, a number of cystic-fibrosis patient organisations asked the governments of Brazil, India, South Africa and Ukraine to invoke compulsory licensing and...
Generic lumacaftor/ivacaftor

Cystic Fibrosis Buyers Club Shows the UK Government The Way

The move by a group of parents of children with cystic fibrosis (CF) to set up a buyers club to gain access to treatments...

“Mutually agreed terms and conditions,” says it all.

On 4 March, Politico reported that the Polish presidency of the Council of the European Union (EU) is expressing doubt that the Pandemic Agreement...

Advanced Purchase Agreements for Covid-19 Vaccines: Do they ensure Global Public Good?

Advanced Purchase Agreements (APAs) were part of a strategy to provide upfront financing for Covid-19 vaccines and to accelerate their development and availability. Since...

Will the European Court of Justice put a stop to the evergreening of Truvada...

Truvada, the fixed-dose combination of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) is a critical medicine in both HIV treatment and prevention. It is...

WTO Members discuss proposal to suspend certain intellectual property protection during the Covid-19 crisis

An earlier version of this comment was published by The Wire on 13 October 2020. On 2 October, India and South Africa sent a proposal...

Wrapping up 2024: Noteworthy events in medicines law and policy around the globe

Welcome to Medicines Law & Policy’s  end of the year blog, our highly biased annual overview of memorable medicines law and policy events. January At the...

Thanks to the European Commission, Biogen can extend Tecfidera monopoly for at least two...

According to an investigation by Follow the Money, a Dutch investigative journalism outlet, the European Commission restored the market exclusivity of Tecfidera, a multiple...

Cystic Fibrosis Medicines Wars in Europe

Monday 4 February, the UK parliament will debate the issuing of a compulsory licence by the government, called ‘Crown use’, for the cystic fibrosis...

Dutch Court Orders AstraZeneca to Pay Damages in Patent Evergreening Case

Today the Dutch court made a long-awaited ruling in the patent evergreening case of health insurance company Menzis versus AstraZeneca. It found that AstraZeneca...